ACLP Concludes with Resounding Success! Wongeny Empowers the Future with Innovation

From March 22 to 24, 2025, the 22nd China International Clinical Laboratory Medicine & Blood Transfusion Instruments and Reagents Expo (CACLP) was grandly held at the Hangzhou Grand Convention and Exhibition Center. Wongeny made a stunning appearance, showcasing its diverse product portfolio. From Molecular Diagnostics POCT and Real-time Fluorescent PCR Analyzers to Ultrasonic Lysis Instruments and Zebrafish series life science instruments, as well as supporting Microfluidic Chip consumables and fully automated microfluidic chip production lines, Wongeny comprehensively demonstrated its integrated tripartite CDMO capabilities in Life Science Instruments + Biochip Consumables + Automation Equipment.

01. Empowering Panoramic Precision Diagnostics

02. Co-creating a New Future for Precision Medicine

During the exhibition, the booth of WONGENY was bustling with visitors, attracting a steady stream of customers from home and abroad. Many industry peers, long-term partners and medical institutions came to our booth to learn about product specifications, technical advantages and cooperation models in depth. We reached preliminary cooperation intentions with clients from India, South Korea, Germany, Russia and other countries on site. Our partners spoke highly of the international quality and innovative technologies of Wanguiyuan's products. During exchanges, we noticed that Wanguiyuan's strategic layout and comprehensive solution capabilities including CDMO services are gaining growing recognition among customers both domestically and globally.

03. New Technologies Pave the Way for Life Sciences

Emerging Technologies Lead the Future The IVD sector and the broader life science industry focus on human diagnostic testing. Characterized by diversified demands, interdisciplinary integration and segmented individual markets, the industry has to improve efficiency through industrial specialization, which is likely to be the mainstream development trend for China's IVD industry. Translating technology into commercial products hinges on mass manufacturing capacity. Founders with biological expertise need strong manufacturing teams to drive product iteration: realizing development from 0 to 1, scaling up from 1 to 100, and achieving mass production from 100 to 10,000 units. Moving forward, we will continue to deepen our efforts in the IVD field. With superior products and services, we strive to contribute to global public health. We also look forward to cooperating with more partners to create new prospects in laboratory medicine and in vitro diagnostics.
CACLP 2025 Wanguiyuan, Suzhou

During the exhibition, the Wongeny booth attracted a constant stream of visitors, drawing crowds from both domestic and international markets. Industry peers, medical institutions, and enterprise clients engaged deeply with our team, exploring product specifications, technical advantages, and collaboration models. On-site, we reached preliminary cooperation agreements with clients from India, South Korea, Germany, Russia, and other countries. Partners expressed high appreciation for the international quality standards and innovative technologies embodied in Wongeny's products. These interactions affirmed that our strategic layout and holistic CDMO solutions are increasingly gaining recognition from the global client base.

03. Pioneering Life Sciences with Cutting-edge Technology

The new wave of technology leads the way forward. The IVD and broader life sciences industry-centered on human diagnostics-is characterized by diverse demands, interdisciplinary integration, and fragmented niche markets. Efficiency can only be achieved through specialized industrial division of labor, which represents the inevitable trajectory for China's IVD sector. Transforming technology into commercial products hinges on scalable manufacturing capabilities. This requires life science entrepreneurs to build robust manufacturing teams capable of scaling products from "0 to 1," "1 to 100," and "100 to 10,000." Moving forward, Wongeny will continue to deepen its roots in the IVD field, delivering superior products and services to contribute to global human health. We look forward to collaborating with more partners to draw a new blueprint in clinical laboratory medicine and in-vitro diagnostics.